Full-Time
Confirmed live in the last 24 hours
Develops monoclonal antibodies for infectious diseases
$235.5k - $329.5kAnnually
Expert
No H1B Sponsorship
San Francisco, CA, USA
Must be in-office 4 days per week.
You match the following Vir Biotechnology's candidate preferences
Employers are more likely to interview you if you match these preferences:
Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$640.6M
Headquarters
San Francisco, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.
Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.
Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.
Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.